CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
CNS Pharmaceuticals Inc <CNSP.OQ> expected to post a loss of 24 cents a share - Earnings Preview
CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to report resultson August 12 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for CNS Pharmaceuticals Inc is for a loss of 24 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for CNS Pharmaceuticals Inc is $10.00, about 85.9% above its last closing price of $5.38
This summary was machine generated August 10 at 20:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026